No Data
Zhejiang Hisun Pharmaceutical (600267.SH): Meropenem is currently still in the first round of centralized procurement period, with small sales volume
Gelonghui reported on November 15 that zhejiang hisun pharmaceutical (600267.SH) stated on the interactive platform that meropenem is currently still in the first round of centralized procurement period, and the sales volume is not large. The company will closely monitor subsequent procurement opportunities; the company has many products and is recovering well through diversified operation. The entire company is striving to reach the performance targets set at the beginning of the year, with the industrial team continuously improving process levels. The cost reduction and efficiency enhancement work has shown initial results this year, and substantial progress in industrial capacity recovery is expected to begin next year.
China Approves Hisun Pharma's Two Medications for Dogs
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Its Share Price
Haizheng Pharmaceutical: Zhejiang Haizheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Zhejiang Haizheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Zhejiang Hisun Pharmaceutical (600267.SH): The net income for the first three quarters was 0.515 billion yuan, a year-on-year increase of 16.49%.
Gelonghui October 30th | Zhejiang Hisun Pharmaceutical (600267.SH) released its third quarter report, with revenue for the first three quarters at 7.87 billion yuan, a decrease of 9.50% year-on-year, net income at 0.515 billion yuan, an increase of 16.49% year-on-year, non-GAAP net income at 0.346 billion yuan, an increase of 8.80% year-on-year, and basic earnings per share at 0.44 yuan.
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
No Data
